Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

Mantia Karampetsou, Mustafa T. Ardah, Maria Semitekolou, Alexia Polissidis, Martina Samiotaki, Maria Kalomoiri, Nour Majbour, Georgina Xanthou, Omar Ali El-Agnaf, Kostas Vekrellis

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Approximately 90% of alpha-synuclein (α-Synuclein) deposited in Lewy bodies is phosphorylated at serine 129 suggesting that the accumulation of phosphorylated α-Synuclein is critical in the pathogenesis of Parkinson's disease. However, in vivo experiments addressing the role of phosphorylated α-Synuclein in the progression of Parkinson's disease have produced equivocal data. To clarify a role of Ser129 phosphorylation of α-Synuclein in pathology progression we performed stereotaxic injections targeting the mouse striatum with three fibrilar α-Synuclein types: wt-fibrils, phosphorylated S129 fibrils and, phosphorylation incompetent, S129A fibrils. Brain inoculation of all three fibrilar types caused seeding of the endogenous α-Synuclein. However, phosphorylated fibrils triggered the formation of more α-Synuclein inclusions in the Substantia Nigra pars compacta (SNpc), exacerbated pathology in the cortex and caused dopaminergic neuronal loss and fine motor impairment as early as 60 days post injection. Phosphorylated fibril injections also induced early changes in the innate immune response including alterations in macrophage recruitment and IL-10 release. Our study further shows that S129 phosphorylation facilitated α-Synuclein fibril uptake by neurons. Our results highlight the role of phosphorylated fibrilar α-Synuclein in pathology progression in vivo and suggest that targeting phosphorylated α-Synuclein assemblies might be important for delaying inclusion formation.

Original languageEnglish
Article number16533
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Synucleins
alpha-Synuclein
Pathology
Phosphorylation
Injections
Parkinson Disease
Lewy Bodies
Innate Immunity
Interleukin-10
Serine
Macrophages

ASJC Scopus subject areas

  • General

Cite this

Karampetsou, M., Ardah, M. T., Semitekolou, M., Polissidis, A., Samiotaki, M., Kalomoiri, M., ... Vekrellis, K. (2017). Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Scientific Reports, 7(1), [16533]. https://doi.org/10.1038/s41598-017-15813-8

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. / Karampetsou, Mantia; Ardah, Mustafa T.; Semitekolou, Maria; Polissidis, Alexia; Samiotaki, Martina; Kalomoiri, Maria; Majbour, Nour; Xanthou, Georgina; Ali El-Agnaf, Omar; Vekrellis, Kostas.

In: Scientific Reports, Vol. 7, No. 1, 16533, 01.12.2017.

Research output: Contribution to journalArticle

Karampetsou, M, Ardah, MT, Semitekolou, M, Polissidis, A, Samiotaki, M, Kalomoiri, M, Majbour, N, Xanthou, G, Ali El-Agnaf, O & Vekrellis, K 2017, 'Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice', Scientific Reports, vol. 7, no. 1, 16533. https://doi.org/10.1038/s41598-017-15813-8
Karampetsou M, Ardah MT, Semitekolou M, Polissidis A, Samiotaki M, Kalomoiri M et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Scientific Reports. 2017 Dec 1;7(1). 16533. https://doi.org/10.1038/s41598-017-15813-8
Karampetsou, Mantia ; Ardah, Mustafa T. ; Semitekolou, Maria ; Polissidis, Alexia ; Samiotaki, Martina ; Kalomoiri, Maria ; Majbour, Nour ; Xanthou, Georgina ; Ali El-Agnaf, Omar ; Vekrellis, Kostas. / Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{d9071daa17c147689a353a1593f3b371,
title = "Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice",
abstract = "Approximately 90{\%} of alpha-synuclein (α-Synuclein) deposited in Lewy bodies is phosphorylated at serine 129 suggesting that the accumulation of phosphorylated α-Synuclein is critical in the pathogenesis of Parkinson's disease. However, in vivo experiments addressing the role of phosphorylated α-Synuclein in the progression of Parkinson's disease have produced equivocal data. To clarify a role of Ser129 phosphorylation of α-Synuclein in pathology progression we performed stereotaxic injections targeting the mouse striatum with three fibrilar α-Synuclein types: wt-fibrils, phosphorylated S129 fibrils and, phosphorylation incompetent, S129A fibrils. Brain inoculation of all three fibrilar types caused seeding of the endogenous α-Synuclein. However, phosphorylated fibrils triggered the formation of more α-Synuclein inclusions in the Substantia Nigra pars compacta (SNpc), exacerbated pathology in the cortex and caused dopaminergic neuronal loss and fine motor impairment as early as 60 days post injection. Phosphorylated fibril injections also induced early changes in the innate immune response including alterations in macrophage recruitment and IL-10 release. Our study further shows that S129 phosphorylation facilitated α-Synuclein fibril uptake by neurons. Our results highlight the role of phosphorylated fibrilar α-Synuclein in pathology progression in vivo and suggest that targeting phosphorylated α-Synuclein assemblies might be important for delaying inclusion formation.",
author = "Mantia Karampetsou and Ardah, {Mustafa T.} and Maria Semitekolou and Alexia Polissidis and Martina Samiotaki and Maria Kalomoiri and Nour Majbour and Georgina Xanthou and {Ali El-Agnaf}, Omar and Kostas Vekrellis",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-15813-8",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

AU - Karampetsou, Mantia

AU - Ardah, Mustafa T.

AU - Semitekolou, Maria

AU - Polissidis, Alexia

AU - Samiotaki, Martina

AU - Kalomoiri, Maria

AU - Majbour, Nour

AU - Xanthou, Georgina

AU - Ali El-Agnaf, Omar

AU - Vekrellis, Kostas

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Approximately 90% of alpha-synuclein (α-Synuclein) deposited in Lewy bodies is phosphorylated at serine 129 suggesting that the accumulation of phosphorylated α-Synuclein is critical in the pathogenesis of Parkinson's disease. However, in vivo experiments addressing the role of phosphorylated α-Synuclein in the progression of Parkinson's disease have produced equivocal data. To clarify a role of Ser129 phosphorylation of α-Synuclein in pathology progression we performed stereotaxic injections targeting the mouse striatum with three fibrilar α-Synuclein types: wt-fibrils, phosphorylated S129 fibrils and, phosphorylation incompetent, S129A fibrils. Brain inoculation of all three fibrilar types caused seeding of the endogenous α-Synuclein. However, phosphorylated fibrils triggered the formation of more α-Synuclein inclusions in the Substantia Nigra pars compacta (SNpc), exacerbated pathology in the cortex and caused dopaminergic neuronal loss and fine motor impairment as early as 60 days post injection. Phosphorylated fibril injections also induced early changes in the innate immune response including alterations in macrophage recruitment and IL-10 release. Our study further shows that S129 phosphorylation facilitated α-Synuclein fibril uptake by neurons. Our results highlight the role of phosphorylated fibrilar α-Synuclein in pathology progression in vivo and suggest that targeting phosphorylated α-Synuclein assemblies might be important for delaying inclusion formation.

AB - Approximately 90% of alpha-synuclein (α-Synuclein) deposited in Lewy bodies is phosphorylated at serine 129 suggesting that the accumulation of phosphorylated α-Synuclein is critical in the pathogenesis of Parkinson's disease. However, in vivo experiments addressing the role of phosphorylated α-Synuclein in the progression of Parkinson's disease have produced equivocal data. To clarify a role of Ser129 phosphorylation of α-Synuclein in pathology progression we performed stereotaxic injections targeting the mouse striatum with three fibrilar α-Synuclein types: wt-fibrils, phosphorylated S129 fibrils and, phosphorylation incompetent, S129A fibrils. Brain inoculation of all three fibrilar types caused seeding of the endogenous α-Synuclein. However, phosphorylated fibrils triggered the formation of more α-Synuclein inclusions in the Substantia Nigra pars compacta (SNpc), exacerbated pathology in the cortex and caused dopaminergic neuronal loss and fine motor impairment as early as 60 days post injection. Phosphorylated fibril injections also induced early changes in the innate immune response including alterations in macrophage recruitment and IL-10 release. Our study further shows that S129 phosphorylation facilitated α-Synuclein fibril uptake by neurons. Our results highlight the role of phosphorylated fibrilar α-Synuclein in pathology progression in vivo and suggest that targeting phosphorylated α-Synuclein assemblies might be important for delaying inclusion formation.

UR - http://www.scopus.com/inward/record.url?scp=85036508920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036508920&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-15813-8

DO - 10.1038/s41598-017-15813-8

M3 - Article

AN - SCOPUS:85036508920

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16533

ER -